First-line (1L) osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): FLAURA2 Asian cohort

被引：1

作者：

Yang, J. C-H. ^{[1
,2
]}

Kobayashi, K. ^{[3
]}

Chewaskulyong, B. ^{[4
]}

Tran, T. V. ^{[5
]}

Biswas, B. ^{[6
]}

Lee, K. H. ^{[7
]}

Feng, P-H. ^{[8
]}

Pham, X. D. ^{[9
]}

Yao, Y. ^{[10
]}

Kuyama, S. ^{[11
]}

Bing, J. Y. Tan Chun ^{[12
]}

Bhise, R. ^{[13
,14
]}

Ahn, M-J. ^{[15
]}

Sriuranpong, V. ^{[16
,17
]}

Li, R. K. ^{[18
]}

Monterroso, E. Armenteros ^{[19
]}

Barrett, K. ^{[20
]}

Albayaty, M. ^{[21
]}

Cheng, Y. ^{[22
]}

机构：

[1] Natl Taiwan Univ Hosp, Dept Med Oncol, Taipei, Taiwan

[2] Natl Taiwan Univ, Grad Inst Oncol, Taipei, Taiwan

[3] Saitama Med Univ, Int Med Ctr, Dept Resp Med, Hidaka, Japan

[4] Chiang Mai Univ, Dept Med, Chiang Mai, Muang, Thailand

[5] Univ Med Ctr, Dept Chemotherapy, Ho Chi Minh City, Vietnam

[6] Tata Med Ctr, Dept Med Oncol, Kolkata, India

[7] Chungbuk Natl Univ, Dept Internal Med, Cheongju, South Korea

[8] Taipei Med Univ, Shuang Ho Hosp, Dept Internal Med, Taipei, Taiwan

[9] HCMC Oncol Hosp, Dept Med Oncol, Ho Chi Minh City, Vietnam

[10] Xi An Jiao Tong Univ, Affiliated Hosp 1, Med Oncol, Xian, Peoples R China

[11] Natl Hosp Org Iwakuni Clin Ctr, Dept Resp Med, Iwakuni, Japan

[12] Cebu Doctors Univ Hosp, Dept Internal Med, Cebu, Philippines

[13] JN Med Coll, Dept Med Oncol, Belagavi, India

[14] KLES Dr Prabhakar Kore Hosp & MRC, Belagavi, India

[15] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea

[16] Chulalongkorn Univ, Fac Med, Div Med Oncol, Bangkok, Thailand

[17] King Chulalongkorn Mem Hosp, Bangkok, Thailand

[18] St Lukes Med Ctr, Inst Canc, Quezon City, Philippines

[19] AstraZeneca, Oncol R&D, Late Stage Dev, Barcelona, Spain

[20] AstraZeneca, Oncol R&D, Late Stage Dev, Biometr, Cambridge, England

[21] AstraZeneca, Oncol R&D, Late Stage Dev, Cambridge, England

[22] Jilin Canc Hosp, Dept Oncol, Changchun, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.10.663

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

630MO

引用

页码：S1635 / S1636

页数：3

共 50 条

[31] Effectiveness of osimertinib plus chemotherapy and avastin for EGFR-mutated advanced non-small cell lung cancer with brain metastases
Qin, H.
Wang, S.
Gao, F.
Zeng, Z.
Liu, X.
ANNALS OF ONCOLOGY, 2021, 32 : S967 - S967
[32] Effectiveness of osimertinib plus chemotherapy and avastin for untreated EGFR-mutated advanced non-small cell lung cancer.
Wang, Fang
Liu, Hui
Zeng, Zhen
Wang, Shasha
Qin, Haifeng
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[33] Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer
Santarpia, Mariacarmela
Menis, Jessica
Chaib, Imane
Cao, Maria Gonzalez
Rosell, Rafael
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (09) : 831 - 840
[34] Furmonertinib plus icotinib for first-line treatment of EGFR-mutated non-small cell lung cancer
Chen, H.
Lin, M.
Jiang, J.
Liu, M.
Lai, Z.
Luo, Y.
Ye, H.
Chen, H.
Yang, Z.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S55 - S55
[35] First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer
Shen, Lan
Qiang, Tan
Li, Ziming
Ding, Ding
Yu, Yongfeng
Lu, Shun
CANCER MEDICINE, 2020, 9 (10): : 3310 - 3318
[36] Final Overall Survival Results from the FLAURA Trial: a Phase III Study on Osimertinib in EGFR-Mutated Advanced Non-small Cell Lung Cancer
Wang, Yue
Nan, Juan
JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2020, 8 (02): : 27 - 29
[37] The efficacy of afatinib combined with bevacizumab in first-line treatment of EGFR-mutated advanced non-small cell lung cancer.
Liu, Yangli
Chen, Haihong
Liang, Wei
Kuang, Yukun
Guo, Yubiao
Tang, Ke-Jing
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[38] First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments
Nie, Naifu
Li, Jianghua
Zhang, Jian
Dai, Jie
Liu, Zhulin
Ding, Zhenyu
Wang, Yubo
Zhu, Mengxiao
Hu, Chen
Han, Rui
Tang, Huan
Li, Li
He, Yong
CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16
[39] Cost-effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR-mutated advanced non-small cell lung cancer
Tian, Wentao
Niu, Lishui
Zhou, Rongrong
Wang, Ziqi
Ning, Jiaoyang
Lu, Ruoyu
Shi, Yin
Tan, Zhaohua
CANCER MEDICINE, 2024, 13 (16):
[40] Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study
Saito, Ryota
Sugawara, Shunichi
Ko, Ryo
Azuma, Koichi
Morita, Ryo
Maemondo, Makoto
Oizumi, Satoshi
Takahashi, Kazuhisa
Kagamu, Hiroshi
Tsubata, Yukari
Seike, Masahiro
Kikuchi, Toshiaki
Okamoto, Isamu
Satoshi, Morita
Asahina, Hajime
Tanaka, Kentaro
Sugio, Kenji
Kobayashi, Kunihiko
EUROPEAN JOURNAL OF CANCER, 2023, 185 : 83 - 93

← 1 2 3 4 5 →